AripaScience · Data · Intelligence
Platform · MolecuLens

Intelligence Beyond Discovery

Repurposing, reformulation, and first-to-file generics in one decision environment. MolecuLens ranks high-value opportunities across regulatory, clinical, patent, commercial, and manufacturing intelligence — months of analysis in days.

3
opportunity pillars
5
intelligence domains
Scored
evidence-backed recommendations
FTF ready
patent-cliff analytics
← All platforms
Capabilities

What MolecuLens does

Who it's for

Built for the teams who decide

Business DevelopmentPortfolio StrategyRegulatory AffairsGeneric Drug Teams
Why MolecuLens

Key differentiators

Repurposing scores weighted by evidence quality, not just publication volume.

Patent FTO analysis runs inside the platform — no external vendor needed.

First-to-file radar covers Para IV filings in real time as they hit the FDA Orange Book.

Reports exportable as structured briefs for BD or licensing discussions.

Ask MolecuLens anything

Natural-language questions MolecuLens answers in seconds:

"Which approved CNS molecules have the strongest cross-indication evidence for autoimmune conditions?"
"Are there reformulation opportunities for metformin that fall outside existing patent protection?"
"Which blockbusters face patent expiry in 2026–2028 with no authorised generic yet filed?"

See MolecuLens on your own data.

Book a walkthrough with the right specialist and we'll tailor it to your therapeutic area and the questions your team is asking.

Request a demoExplore other platforms →